PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials. gov identifier: NCT02654132),
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …

Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple
myeloma during the last decade. The use of antibodies as well as antibody drug conjugates …

Multiple myeloma (MM), a stage-developed plasma cell malignancy, evolves from
monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM) …

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface
receptor CD38, which is expressed not only on plasma cells but also on NK cells and …

The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM).
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades
with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome …

The incorporation of immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide) and
proteasome inhibitors (bortezomib, ixazomib, and carfilzomib) in the treatment of multiple …

Introduction: In the last few years, monoclonal antibodies have rapidly modified the
therapeutic strategies for treating patients with multiple myeloma. Areas covered: In this …

Approval of daratumumab (DARA), an IgGk1 monoclonal antibody targeting CD38, for the
treatment of relapsed/refractory multiple myeloma as monotherapy in November 2015 …

Dear Editor, With the advent of immunomodulatory agents (IMiD), proteasome inhibitors (PI),
and anti-CD38 monoclonal antibodies (MoAb), the survival outcomes of patients with …